Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin (Q36624994)

15 August 2017

1 reference

title

Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin (English)

1 reference

15 August 2017

Janet B McGill

1

1 reference

15 August 2017

George L King

2

1 reference

15 August 2017

Paul H Berg

3

1 reference

15 August 2017

Karen L Price

4

1 reference

15 August 2017

Keri A Kles

5

1 reference

15 August 2017

Edward J Bastyr

6

1 reference

15 August 2017

David L Hyslop

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Drug Safety

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

835-845

1 reference

The prevalence of diabetic retinopathy among adults in the United States

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Epidemiology of diabetic retinopathy and macular oedema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Molecular understanding of hyperglycemia's adverse effects for diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

The microvasculature in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

The extended protein kinase C superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Selected novel anticancer treatments targeting cell signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

MAPK mediates PKC-dependent contraction of cat esophageal and lower esophageal sphincter circular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

The significance of QT interval in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Immunodeficiency in protein kinase cbeta-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Protein kinase C in galactosemic and tolrestat-treated lens epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

The effect of ruboxistaurin on nephropathy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

Painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.5.6.835

21 January 2018

Identifiers

DOI

10.1517/14740338.5.6.835

1 reference

15 August 2017

1 reference